Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257820 | 0.93 | ALDH1A1 (0.37) | GAAALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL1655765 | 0.92 | GAA (0.38) | GAAALDH1A1LMNASMN1; SMN2MAPK1 | |
| SCHEMBL1301071 | 0.91 | MAPT (0.38) | GAAALDH1A1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL6730444 | 0.91 | MAPT (0.39) | GAAALDH1A1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL12362363 | 0.91 | STING1 (0.41) | GAAALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL12064247 | 0.90 | MAPT (0.38) | GAAALDH1A1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL1656717 | 0.89 | MET (0.42) | GAAALDH1A1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL1497638 | 0.89 | MAPT (0.39) | GAAALDH1A1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL2258176 | 0.89 | GAA (0.36) | GAAALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL12108530 | 0.89 | ALDH1A1 (0.38) | GAAALDH1A1LMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2244721-A2 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO Ý1,2-C¨QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | Bayer Schering Pharma AG (DE) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009091550-A2 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2009-07-23 | — | — | WO | disclosed |